In some cancers, a type of collagen (type I) tricks cells into becoming more mobile and invasive by turning off a 'stickiness' protein (E-cadherin) and turning on 'migration' proteins (N-cadherin, SNAI1).
Scientific Claim
Collagen type I promotes epithelial-mesenchymal transition (EMT) in breast, lung, and pancreatic cancers by activating integrin α2β1 and DDR1, leading to upregulation of SNAI1, LEF1, and N-cadherin and downregulation of E-cadherin.
Original Statement
“In EMT induction, the interaction between collagen and integrin α2β1 triggers intracellular cascade by activating ILK-dependent phosphorylation of IkB, and increasing the abundance of nuclear-localized NF-κB to upregulate the expression of LEF1 and SNAI1... The communication between β1 integrin subunits and pericellular matrix type I collagen is associated with the indirect induction of N-cadherin and the direct suppression of E-cadherin... DDR1 activates EMT via stimulating the protein expression of N-cadherin and vimentin...”
Evidence Quality Assessment
Claim Status
overstated
Study Design Support
Design cannot support claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The review aggregates findings from cancer cell studies but does not establish causation in humans. 'Promotes' implies direct causal role, which is not supported by the review’s design.
More Accurate Statement
“Collagen type I is associated with promotion of epithelial-mesenchymal transition in breast, lung, and pancreatic cancers through activation of integrin α2β1 and DDR1, correlating with upregulation of SNAI1, LEF1, and N-cadherin and downregulation of E-cadherin based on prior in vitro and animal model studies.”
Evidence from Studies
Supporting (0)
Contradicting (1)
This study talks generally about how collagen interacts with cells and how it can be used in medicine, but it doesn't mention cancer or the specific molecules involved in the claim, so it doesn't help prove or disprove it.